Robert Lentz, MD, received funding to test the combination of two drugs in colorectal and pancreas ductal adenocarcinoma. “Metastatic colorectal and pancreas ductal adenocarcinoma are common and deadly and frequently harbor KRAS mutations, novel treatments are desperately needed.”
Thanks to a grant from the Gilead Sciences Research Scholars Program, University of Colorado Cancer Center member Tejas Patil, MD, is launching a study to better understand how persister cells survive in the presence of targeted therapy and what methods might be used to target them to improve patient survival.
In the earliest days of specialized cancer care, either individual oncologists were burdened with the expectation to know everything, or patients were sent on treatment journeys that could involve multiple visits with multiple clinicians in multiple locations. Drs. Lieu and Kim discuss the benefits of multidisciplinary care.
Dr. Davila received R01 grant funding from the NCI to better understand why some melanoma patients don’t respond to immunotherapy, and to determine how to increase responsiveness in patients, eventually resulting in a Phase I clinical trial in patients with rare melanoma.
Jamie Studts, PhD, has co-created a project designed to boost lung cancer screening rates in Kentucky earning a grant from the Bristol Myers Squibb Foundation.
Dr. Laura Graham, is currently leading a phase 2 trial studying whether high doses of testosterone are a feasible treatment against castration-resistant prostate cancer (CRPC) leading to a reduction in prostate cancer growth as well as improved quality of life.
PIKE-PREP offers students from URM communities multi-dimensional mentorship and research training designed to prepare them for enrollment and success in a top-tier PhD or MD/PhD program.
Jessica McDermott, MD, Assistant Professor with the Division of Medical Oncology, has been named Deputy Associate Director for Diversity and Inclusion in Clinical Research. This role was recently created to identify and address barriers clinical trial accrual.
Robert Lentz, MD, spearheads a new phase 2 clinical trial for patients with metastatic colon cancer for whom chemotherapy and biologic therapy are no longer effective options.
Co-director of the hereditary cancer program, Marie Wood, MD, aims to increase patient awareness surrounding the importance of genetic counseling and genetic testing relating to cancer.
Dr. Kabos discusses his recent study analyzing blood plasma to extract critical breast tumor information and disease progression instead of more invasive tissue biopsies.